Page last updated: 2024-10-24

candesartan and Atrophy

candesartan has been researched along with Atrophy in 2 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.

Research Excerpts

ExcerptRelevanceReference
"With candesartan-based treatment, compared with control, the relative risk of non-fatal stroke was 0."2.43The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses. ( Trenkwalder, P, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsuruya, K1
Yoshida, H1
Trenkwalder, P1

Reviews

1 review available for candesartan and Atrophy

ArticleYear
The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2006, Volume: 24, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrophy; Benzimidazoles; Bip

2006

Other Studies

1 other study available for candesartan and Atrophy

ArticleYear
Brain Atrophy and Cognitive Impairment in Chronic Kidney Disease.
    Contributions to nephrology, 2018, Volume: 196

    Topics: Animals; Atrophy; Benzimidazoles; Biphenyl Compounds; Brain; Cognitive Dysfunction; Cyclic N-Oxides;

2018